SYX-5219 is a first-in-class oral PKM2 modulator designed to drive sustained disease remission across a range of autoimmune diseases Phase 1b trial to...
The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are bei...
Concept Life Sciences, a leading contract research organisation (CRO) serving the global life sciences and pharma industry, announces the official openin...
Kindeva, a global CDMO and drug delivery expert, has officially opened its new UK headquarters at Charnwood Campus Science Innovation and Technology Park...
AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, annou...
Cenevo is launching the Labguru Assistant, an AI-enabled extension to the Labguru solution designed to provide scientists with real-time, in-platform suppo...
HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist being investigated to treat a wide range of solid cancers in combinati...
Quotient Sciences, a leading global drug development and manufacturing accelerator, and UK technology innovation centre, CPI, have signed a memorandum of...
CDT Equity Inc. announces that it has successfully identified a new biological target and novel therapeutic indication for its lead programme, AZD1...
Sygnature Discovery, a leading integrated drug discovery contract research organisation (CRO), today announces the completion of a major enhancemen...
iFIT, a global leader in connected fitness and interactive content, announced a groundbreaking partnership with Samsung Health, one of the world&rs...
Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, announces that the U.S. Food and Drug A...
Conduit Pharmaceuticals Inc. announces the filing of four new patent applications relating to its key assets AZD1656 and AZD5658, including the Com...
Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford BioTherapeutics’ proprietary OGA...
© 2025 Biopharma Boardroom. All Rights Reserved.
